Related Experiment Videos
Orelox (cefodoxime) in typhoid fever.
A Dhanjee1, M A Sheikh, M Yaqub
1Dhanjee Clinic, Clifton, Karachi.
JPMA. the Journal of the Pakistan Medical Association
|December 22, 1999
Summary
Cefodoxime (Orelox) demonstrated 86% efficacy in treating pediatric typhoid fever, showing significant clinical improvement. This study suggests it is a safe and effective option for children with this common infection.
Area of Science:
- Pediatric infectious diseases
- Pharmacology and therapeutics
Background:
- Typhoid fever remains a significant public health concern in children, particularly in endemic regions.
- Effective antibiotic treatment is crucial for managing typhoid fever and preventing complications.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of Cefodoxime (Orelox) for treating typhoid fever in pediatric patients.
Main Methods:
- An open-label, non-comparative, multicenter study was conducted across general practice settings in Pakistan.
- The study included 77 children aged 1-15 years with a confirmed diagnosis of typhoid fever based on a positive Widal test.
Main Results:
- Overall, 86% of the pediatric patients achieved a clinical cure or improvement.
- Specifically, 79% were cured, and 7% showed improvement in signs and symptoms, while 14% experienced treatment failure.
Conclusions:
- Cefodoxime (Orelox) exhibited an 86% efficacy rate in producing clinical responses in children with typhoid fever.
- The findings suggest that Cefodoxime is a safe and effective therapeutic option for pediatric typhoid fever management.